EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections

Simone Tunesi, Adrian Zelazny, Zeina Awad, Faiza Mougari, Julien M Buyck, Emmanuelle Cambau

Clinical Microbiology and Infection · 2024-06 · 30 (6) · 718-725

DOI: 10.1016/j.cmi.2023.09.019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2024-06. Verfasst von Simone Tunesi und 5 weiteren Autor:innen. Beteiligte Einrichtung: UOC Malattie infettive, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Microbial Sensitivity Tests, Anti-Bacterial Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Joint Programming Initiative on Antimicrobial Resistance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mycobacterium abscessus (MAB) is the mycobacterial species least susceptible to antimicrobials. Infections are difficult to treat, and cure rates are below 50% even after a combination of 4-5 drugs for many months. OBJECTIVES: To examine antimicrobial susceptibilities and treatment recommendations in light of what is known about mechanisms of resistance and pharmacodynamics/pharmacokinetics (PK/PD) interactions. SOURCES: Original papers on the topics of 'antimicrobials', 'susceptibility', 'treatment', and 'outcome' from 2019 onwards, in the context of the evidence brought by the guidelines published in 2020 for pulmonary infections. CONTENT: MAB is susceptible in vitro to only a few antimicrobials. Breakpoints were set by the Clinical and Laboratory Standards Institute and are revised by the European Committee on Antimicrobial Susceptibility Testing for epidemiological cut-off values. Innate resistance is due to multiple resistance mechanisms involving efflux pumps, inactivating enzymes, and low drug-target affinity. In addition, MAB may display acquired resistance to macrolides and amikacin through mutations in drug binding sites. Treatment outcomes are better for macrolide-based combinations and MAB subspecies massiliense. New compounds in the family of cyclines, oxazolidinones, and penem-β-lactamase inhibitor combinations (described in another paper), as well as bedaquiline, a new antituberculous agent, are promising, but their efficacy remains to be proven. PK/PD studies, which are critical for establishing optimal dosing regimens, were mainly done for monotherapy and healthy individuals. IMPLICATIONS: Medical evidence is poor, and randomized clinical trials or standardized cohorts are needed to compare outcomes of patients with similar underlying disease, clinical characteristics, and identified MAB subspecies/sequevar. Microbiological diagnosis and susceptibility testing need to be harmonized to enable the comparison of agents and the testing of new compounds. Testing antimicrobial combinations requires new methods, especially for PK/PD parameters. Molecular testing may help in assessing MAB resistance prior to treatment. New antimicrobials need to be systematically tested against MAB to find an effective antimicrobial regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousMicrobial Sensitivity TestsAnti-Bacterial AgentsHumansDrug Resistance, BacterialRespiratory Tract Infections

Stichwörter der Autor:innen

AbscessusAntimicrobial susceptibilityAntimicrobial treatmentNontuberculous mycobacteriaPK/PDResistance mechanisms

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • UOC Malattie infettive, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
  • Service de mycobactériologie spécialisée et de référence, Laboratoire associé du CNR des mycobactéries et de la résistance des mycobactéries aux antituberculeux (CNR-MyRMA) APHP GHU Paris Nord, Hôpital Bichat, Paris, Fr…
  • Université de Poitiers, PHAR2, Inserm UMR 1070, Poitiers, France.

Förderung

  • Agence Nationale de la Recherche
  • Joint Programming Initiative on Antimicrobial Resistance

Zitieren

APA

Tunesi, S., Zelazny, A., Awad, Z., Mougari, F., Buyck, J. M., & Cambau, E. (2024). Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections. Clinical Microbiology and Infection, 30(6), 718-725. https://doi.org/10.1016/j.cmi.2023.09.019

Vancouver

Tunesi S, Zelazny A, Awad Z, Mougari F, Buyck JM, Cambau E. Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections. Clinical Microbiology and Infection. 2024;30(6):718-725. doi:10.1016/j.cmi.2023.09.019

BibTeX
@article{Tunesi2024,
  author = {Tunesi, Simone and Zelazny, Adrian and Awad, Zeina and Mougari, Faiza and Buyck, Julien M and Cambau, Emmanuelle},
  title = {Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections},
  journal = {Clinical Microbiology and Infection},
  year = {2024},
  volume = {30},
  number = {6},
  pages = {718--725},
  doi = {10.1016/j.cmi.2023.09.019}
}
Kostenlos starten →